Sort
21,281 grants matching “influenza”
CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells
$801,617Paul Michael Armistead · Cell Microsystems, Inc. · R42 · FY2018 · AI
Mechanisms of CMV Replication on HIV Persistence
$801,604Sara Gianella Weibel · University Of California, San Diego · R01 · FY2021 · AI
HIV B-Cell Lineage Vaccine Design Based on Replicating SAd and Env Protein in NHP
$801,463Jeffery Alexander · Paxvax, Inc. · R44 · FY2015 · AI
CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells
$801,389Paul Michael Armistead · Cell Microsystems, Inc. · R42 · FY2017 · AI
Core_Prospective population-based estimation of influenza vaccine effectiveness a
$801,316Michael L Jackson · Kaiser Foundation Health Plan Of Washington · U01 · FY2015 · IP
Core_RT-PCR based Case-Control: Apt Measure of Influenza Vaccine Effectiveness
$801,316Manjusha Gaglani · Scott And White Memorial Hospital · U01 · FY2015 · IP
Development of highly potent human monoclonal for RSV immuno-prophylaxis
$801,020Larry Zeitlin · Mapp Biopharmaceutical, Inc. · R44 · FY2021 · AI
The Impacts of Adverse Provider Conditions on Provider Bias and Health Disparities
$800,983Anastasia Makhanova · University Of Arkansas At Fayetteville · R01 · FY2024 · MD
Centers of Excellence for Influenza Research and Surveillance
$800,840John Jay Treanor · University Of Rochester · N01 · FY2018 · AI
A prophylactic vaccine to prevent colonization by Pseudomonas aeruginosa
$800,748Wendy L Picking · University Of Missouri-Columbia · R01 · FY2023 · AI
Influenza Viral Genomics and Evolution
$800,725Jeffery Taubenberger · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Text4Vax: Understanding the Implementation of Informational Text Messages for Pediatric Influenza Vaccines
$800,674Melissa S Stockwell · Columbia University Health Sciences · R01 · FY2025 · AI
Engineering protease-resistant alpha-beta peptides for broad-spectrum antivirals
$800,168Anne Moscona · Weill Medical Coll Of Cornell Univ · R01 · FY2015 · AI
Model Development, Data Analysis, and Simulation for Affinity Maturation
$800,116Thomas B Kepler · Boston University Medical Campus · U19 · FY2017 · AI
A systems immunology approach for predicting poor responses to Hepatitis B vaccination
$800,116Ramin Herati · New York University School Of Medicine · R01 · FY2023 · AI
Adjuvant Comparison and Characterization
$800,000Philip Felgner · University Of California-Irvine · N01 · FY2024 · AI
SUPPORTING INFLUENZA VACCINE INTRODUCTION IN LOW-MIDDLE INCOME COUNTRIES
$800,000David Wood · World Health Organization · U01 · FY2011 · FD
Systems biological assessment of vaccination-induced protective immunity in African children
$800,000Bali Pulendran · Stanford University · U01 · FY2023 · AI
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.
$800,000Manjusha Gaglani · Scott And White Memorial Hospital · U01 · FY2017 · IP
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.
$800,000Manjusha Gaglani · Scott And White Memorial Hospital · U01 · FY2016 · IP
Adjuvant Comparison and Characterization in Influenza , Chlamydia muridarum, and Coxiella burnetii Vaccines
$800,000Philip Felgner · University Of California-Irvine · N01 · FY2023 · AI
RECENT OUTBREAKS OF BIRD FLU (H5N1) IN U.S. CATTLE HAVE RAISED CONCERNS ABOUT HOW FLU VIRUSES SPREAD IN LIVESTOCK. HOWEVER, ANOTHER LESSER-KNOWN VIRUS, INFLUENZA D (IDV), IS ALREADY PRESENT IN CATTLE WORLDWIDE AND EVOLVING RAPIDLY. WHILE IDV WAS INITIALLY THOUGHT TO CAUSE ONLY MILD ILLNESS, NEWER STRAINS ARE NOW LEADING TO SERIOUS RESPIRATORY DISEASE IN CALVES. EVEN MORE CONCERNING, IDV CAN INFECT OTHER FARM ANIMALS AND EVEN HUMANS, POSING A BROADER RISK TO AGRICULTURE AND PUBLIC HEALTH.CURRENTLY, THERE ARE NO RELIABLE ANTIBODY DETECTION TESTS TO TRACK THE EXPOSURE OF CATTLE TO IDV AND NO VACCINES TO PROTECT CATTLE, LEAVING THE LIVESTOCK INDUSTRY VULNERABLE. WITHOUT ACTION, IDV COULD BECOME A SIGNIFICANT THREAT TO CATTLE HEALTH, FARMERS' LIVELIHOODS, AND THE STABILITY OF U.S. AGRICULTURE.TO ADDRESS THIS, EXPERTS, THE TEAM LED BY THE UNIVERSITY OF PITTSBURGH IN COLLABORATION WITH SCIENTISTS FROM SOUTH DAKOTA STATE UNIVERSITY ARE WORKING TOGETHER ON TWO CRITICAL SOLUTIONS. FIRST, WE ARE DEVELOPING NEW DIAGNOSTIC TESTS TO MONITOR IDV IN CATTLE AND OTHER LIVESTOCK. SECOND, WE ARE DEVELOPING AN INNOVATIVE NASAL SPRAY VACCINE TO PROTECT CATTLE FROM IDV AND PREVENT THE DISEASE FROM SPREADING.BY PROACTIVELY DEVELOPING BETTER MONITORING TOOLS AND A VACCINE, THIS RESEARCH WILL HELP SAFEGUARD CATTLE, SUPPORT US CATTLE INDUSTRY, AND STRENGTHEN THE SUSTAINABILITY AND PROFITABILITY OF THE U.S. LIVESTOCK INDUSTRY.
$800,000University Of Pittsburgh - Of The Commonwealth System Of Higher Education · · FY2025 · National Institute of Food and Agriculture
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** DISEASES OF SWINE ARE CAUSED BY THE PRRS VIRUS (PRRSV). PRRSV CONTINUES TO DISTRESS THE GLOBAL PORK INDUSTRY BY CAUSING ECONOMIC LOSSES ESTIMATED AT $664 MILLION EVERY YEAR DUE TO REPRODUCTIVE FAILURE, FATAL RESPIRATORY DISEASE, AND SUBSEQUENT SECONDARY BACTERIAL INFECTION.SWINE INFLUENZA VIRUS (SIV) CAUSES ACUTE RESPIRATORY DISEASES IN BREEDING AND NURSERY PIGS AND CAN PREDISPOSE THE INFECTED ANIMALS TO SECONDARY VIRAL AND BACTERIAL INFECTIONS. IN ADDITION TO THE ADVERSE ECONOMIC IMPACT ON PIG PRODUCERS, SIV IS ALSO A ZOONOTIC PATHOGEN DETRIMENTAL TO HUMANS. COINFECTIONOF PIGS WITH PRRSV, PORCINE CIRCOVIRUS TYPE 2 (PCV2), AND SIV ON THE SAME FARMS ALSO PLAYS A CRITICAL ROLE IN THE PORCINE RESPIRATORY DISEASE COMPLEX AND IS FREQUENTLY REPORTED.SINCE THE LATE 1990S, KILLED AND MODIFIED LIVE VIRUS (MLV) PRRSV VACCINES BASED ON ATTENUATED EUROPEAN OR NORTH AMERICAN PRRSV STRAINS HAVE BEEN COMMERCIALIZED AND USED TO CONTROL PRRS. THE MLV-PRRS VACCINE HAS SAFETY ISSUES DUE TO THE PERSISTENCE OF THE VACCINE VIRUS IN THE HOST AND INCREASED MUTATION RATES. CONSEQUENTLY, VACCINE-LIKE VIRULENT PRRSV STRAINS HAVE EMERGED AND CAUSED VACCINE FAILURES INSTEAD OF PROTECTING THE PIGS. LIKEWISE, CURRENTLY AVAILABLE INACTIVATED SWINE INFLUENZA VACCINES ARE INEFFECTIVE IN CONTROLLING SIV IN PIGS DUE TO THE STRAIN VARIABILITY.PREVIOUSLY, WE DEVELOPED A QUADRUPLE GENE-DELETED PSEUDORABIES VIRUS (PRVQMV) VACCINE VECTOR PLATFORM IN WHICH ENVELOPE GLYCOPROTEIN GE, US9, GG, AND THYMIDINE KINASE (TK) GENES ARE DELETED. A CHIMERIC PCV2 CAPSID PROTEIN (CAP) WAS ALSO INSERTED, RESULTING IN THE PRVQMV-CAP.IN THIS PROJECT, OUR GOALS ARE TO ENGINEER THE PRVQMV FURTHER, I) TO INCORPORATE THE PRSSV ENVELOPE PROTEINS GLYCOPROTEINS (GP2.GP3,GP4, AND GP5) AND THE MATRIX PROTEIN, AND TEST ITS VACCINE PROTECTIVE EFFICACY AGAINST A VIRULENT PRRSV CHALLENGE STRAIN AND II) TO INCORPORATE THE SIV ENVELOPE GLYCOPROTEINS H1N1 AND H3N2, AND TEST ITS PROTECTIVE EFFICACY AGAINST THE TWO DIFFERENT (H1N1 AND H3N2 STRAINS) VIRULENT INFLUENZA CHALLENGE VIRUSES.
$800,000Louisiana State University · · FY2024 · National Institute of Food and Agriculture
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** AVIAN INFLUENZA (AI) IS AMONG THE MOST ECONOMICALLY IMPORTANT DISEASES AFFECTING POULTRY AND POSES A SIGNIFICANT THREAT TO THE SUSTAINABILITY OF THE POULTRY INDUSTRY WORLDWIDE. OVER THE PAST TWO DECADES, OUTBREAKS OF AI, ESPECIALLY INVOLVING HIGHLY PATHOGENIC AVIAN INFLUENZA (HPAI), HAVE CAUSED SEVERE ECONOMIC LOSSES IN MANY COUNTRIES, INCLUDING THE UNITED STATES (U.S.). NOTABLY, THE SPREAD OF HPAI IN THE U.S. IN 2014-2015 AFFECTED 50 MILLION DOMESTIC BIRDS AND RESULTED IN AN ESTIMATED LOSS OF $3.3 BILLION. CURRENTLY, THE U.S. HAS BEEN FACING ANOTHER DEVASTATING OUTBREAK OF HPAI THAT BEGAN IN 2022 AND AS OF AUGUST 3, 2023 HAS AFFECTED 58.7 MILLION BIRDS IN 47 STATES, SURPASSING THE PREVIOUS RECORD OF 2014-2015 OUTBREAKAND STANDING OUT AS THE MOST SIGNIFICANT ANIMAL DISEASE EVENT IN THE HISTORY OF THE U.S.VACCINATION IS THE MOST COST-EFFECTIVE AND HUMANE METHOD FOR THE CONTROL AND PREVENTION OF VIRAL DISEASES IN LIVESTOCK AND POULTRY. HOWEVER, VIRUSES LIKE AVIAN INFLUENZA VIRUS (AIV), WHICH ARE CONSTANTLY MUTATING, REQUIRE VACCINE PLATFORM(S) THAT CAN BE RAPIDLY DEVELOPED AND DEPLOYED IN RESPONSE TO EMERGING STRAINS. THUS, FLEXIBLE VACCINE PLATFORMS THAT ENABLE RAPID UPDATES ON AIV ANTIGENS TO MATCH CIRCULATING VIRUSES IN ENDEMIC AREAS OR NEWLY EMERGING VIRUSES IN NON-ENDEMIC COUNTRIES ARE NEEDED. WE WILL TACKLE THIS PROBLEMS BY DEVELOPING NOVEL VACCINE DELIVERY PLATFORMS FOR HPAI BASED ON A NEW CONDORPOX VIRUS VECTOR AND ON A SELF-AMPLIFYING RNA TECHNOLOGY PLATFORM. ADDITIONALLY, WE WILL ALSO DEVELOP SEROLOGICAL ASSAYS THAT WILL ENABLE DIFFERENTIATION OF VACCINATED FROM INFECTED ANIMALS. THE OUTCOMES OF THE PROPOSED PROJECT WILL HAVE A SIGNIFICANT IMPACT ON ANIMAL HEALTH AND ON THE SUSTAINABILITY OF THE POULTRY INDUSTRY WORLDWIDE.
$800,000Cornell University · · FY2024 · National Institute of Food and Agriculture
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** ACCORDING TO THE 2021 US AGRICULTURE STATISTICS, THE COMBINED VALUE OF PRODUCTION AND SALES FROM BROILERS, EGGS, TURKEYS, AND CHICKS WAS $46.1 BILLION. UNFORTUNATELY, AVAILABLE VACCINES DO NOT PROVIDE SUFFICIENT PROTECTION AGAINST EMERGING AND TRANSBOUNDARY INFECTIONS SUCH AS HIGHLY PATHOGENIC AVIAN INFLUENZA (HPAI) THAT IMPACTED THE POULTRY INDUSTRY EARLIER IN 2022. WE HYPOTHESIZE THAT DNA-BASED NANOPARTICLE VACCINES (NANOVACCINES) WILL IMPROVE EFFICIENCY AND DELIVERY OF ANTIGENS FOR ROBUST INDUCTION OF PROTECTIVE IMMUNITY AGAINST POULTRY PATHOGENS. RECENTLY, REPORTS FROM OUR GROUP INDICATED THAT A NOVEL NANOADJUVANT SYSTEM (TERMED QAC FOR QUIL-A-TREATED CHITOSAN) COMBINED WITH PLASMID DNA CONSTRUCTS WERE ABLE TO DELIVER VIRAL ANTIGENS AND MOUNT A STRONG, PROTECTIVE IMMUNITY IN CHICKENS AGAINST INFECTIOUS BRONCHITIS VIRUS (IBV). IN THIS PROJECT, WE WILL CAPITALIZE ON OUR EXPERIENCE IN DEVELOPING MOSAIC NANOVACCINES THAT CAN REPRESENT THOUSANDS OF CIRCULATING VIRAL ISOLATES. SPECIFICALLY, WE PLAN TO: FIRST, EXAMINE THE DELIVERY AND STABILITY OF AVIAN INFLUENZA-HEMAGGLUTININ (HA) ANTIGEN. WE WILL UTILIZE VACCINE CONSTRUCTS TO CHARACTERIZE MOSAIC ANTIGEN RELEASE KINETICS AND INFECTIVITY TO CHICKEN CELLS FOLLOWING DIFFERENT TEMPERATURE CONDITIONS THAT MIMIC FIELD APPLICATION. SECOND, WE WILL ANALYZE THE IMMUNOGENICITY OF SEVERAL VACCINE CONSTRUCTS IN CHICKENS USING INTRANASAL AND ORAL ROUTES. FINALLY, WE WILL ANALYZE THE OVERAL VACCINE PROTECTION BY FOLLOWING CHALLENGE WITH LPAI AND HPAI. OVERALL, DEVELOPING EFFECTIVE, SAFE, AND EASY TO ADMINISTER NANOVACCINES WILL SIGNIFICANTLY IMPROVE OUR PREPARATION TO CONTROL EMERGING AND RE-EMERGING INFECTIONS IN POULTRY AND OTHER ANIMALS.
$800,000University Of Wisconsin System · · FY2023 · National Institute of Food and Agriculture